Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Asia Pacific Key To Speeding Up Global Drug Development, Says Quintiles VP Anand Tharmaratnam (Part 1 Of 2)

This article was originally published in PharmAsia News

Executive Summary

Globalization of clinical trials is perhaps Asia's main role in advancing the pharmaceutical industry, says Quintiles Asia Pacific Head of Clinical Development Anand Tharmaratnam, who discussed innovation in Asia Pacific with PharmAsia News' Australia Bureau. Key to that innovation is a lack of legacy informationin that the past is not holding the industry back, and virtual opportunitiesand private/public cooperative partnerships offer ripe benefits.

You may also be interested in...



Quintiles Asia Strategic Planning Director Simranjit Singh On Korea’s Clinical Trial Strategy: An Interview With PharmAsia News

The CRO exec discusses Korea’s expanding role in global clinical trials and the rising interest among MNCs for conducting trials in Korea, as evidenced by Pfizer’s Xalkori.

Korea FDA To Consider Substantial Reduction To IND Timeframe

As Korea competes with neighboring countries to be a regional clinical trial hub, KFDA weighs the advantages of slashing IND timelines from 30 days down to 14 days.

Korea FDA To Consider Substantial Reduction To IND Timeframe

As Korea competes with neighboring countries to be a regional clinical trial hub, KFDA weighs the advantages of slashing IND timelines from 30 days down to 14 days.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC075026

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel